Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc. (NYSE:MRK) posted a major cancer-vaccine trial win.
mRNA Has ‘Tremendous’ Potential
“Despite its obvious misuse during Covid, mRNA has tremendous promise for curing diseases,” Musk said in a post on X. “Artificial RNA essentially makes curing diseases a software problem.”
Musk was replying to Eric Topol, scientist and founder of the Scripps Research Translational Institute, who said that the Phase 3 melanoma trial breakthrough builds on “signs of success” in personalized mRNA vaccines targeting pancreatic cancer, triple-negative breast cancer, and non-small cell lung cancer.
A First-of-Its-Kind Cancer Trial Result
